Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.

Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...

Our new but simple method is far more effective and can now be applied to a much wider range of plant species than our ...

Agreement with IRRI marks Pairwise's third CGIAR partnership, enabling the research institute to use Fulcrum® genome editing technology to develop higher-yielding, more nutritious rice varieties that ...

Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...